Post-Discharge Mortality and Rehospitalization among participants in a Comprehensive Acute Kidney Injury Rehabilitation Program
Background: Hospitalization-associated acute kidney injury (AKI) is common and associated with markedly increased mortality and morbidity. This prospective cohort study examined the feasibility and association of an AKI rehabilitation program with post-discharge outcomes. Methods: Adult patients hospitalized from 9/19/19-2/29/20 in a large health system in Pennsylvania with stage 2-3 AKI who were alive, and not on dialysis or hospice at discharge were evaluated for enrollment. The intervention included patient education, case manager services, and expedited nephrology appointments starting within 1-3 weeks of discharge. We examined the association between AKI rehabilitation program participation and risks of rehospitalization or mortality in logistic regression analyses adjusting for comorbidities, discharge disposition, sociodemographic and kidney parameters. Sensitivity analysis was performed using propensity score matching. Results: Among high-risk AKI patients evaluated, 77/183 were suitable for inclusion. Out of these, 52 (68%) patients were enrolled and compared to 400 contemporary non-participant stage 2/3 AKI survivors. Crude post-discharge rates of rehospitalization or death were lower for participants vs. non-participants at 30 days (15.4% vs 34.2%; p=0.01) and at 90 days (30.8% vs 50.5%; p=0.01). After multivariable adjustment AKI rehabilitation program participation was associated with lower risk of rehospitalization or mortality at 30 days (OR 0.41, 95% CI: 0.16-0.93) with similar findings at 90-days (OR 0.52, 95% CI: 0.25-1.05). Due to small sample size, propensity-matched analyses were limited. The participants' rehospitalization or mortality were numerically lower but not statistically significant at 30 days (17.8% vs. 31.1%; p=0.22) or at 90 days (46.7% vs. 57.8%; p=0.4). Conclusions: The AKI rehabilitation program was feasible and potentially associated with improved 30-day rehospitalization or mortality. Our interventions present a roadmap to improve enrollment in future randomized trials.